RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic ...

A team of researchers from City of Hope and The University of Texas M.D. Anderson Cancer Center has reported safety and ...

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Hold rating on Kyverna Therapeutics, Inc. (KYTX – Research Report). The ...

as well as clarifying the molecular basis of many diseases and developing new therapies. 2 [Alt text] From left to right, the figure outlines key elements of posttranscriptional pre-mRNA splicing: an ...

ME Therapeutics Holdings Inc. Vancouver, British Columbia–(Newsfile Corp. – September 18, 2024) – ME Therapeutics Holdings ...

Keith Speights has positions in Pfizer and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Pfizer, and Vertex Pharmaceuticals. The Motley Fool recommends Moderna. The ...

DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...